'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective

被引:81
作者
Clark, AD [1 ]
Gordon, WC [1 ]
Walker, ID [1 ]
Tait, RC [1 ]
机构
[1] Glasgow Royal Infirm, Dept Haematol, Glasgow G4 0SF, Lanark, Scotland
关键词
coagulopathy; massive blood transfusion; recombinant FVIIa;
D O I
10.1111/j.0042-9007.2004.00393.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives The aim of this retrospective study was to assess the effect of activated recombinant factor VII (rFVIIa) on the natural history of massive transfusion episodes. Materials and Methods During 2002, outcome parameters were assessed in 50 patients transfused with more than 10 units of packed red cells. The effect of the addition of rFVIIa in 10 patients, with intractable bleeding, was then observed. Results Overall mortality was 20% at 24 h and 34% at 7 days. Severe coagulopathy was confirmed as a serious negative prognostic factor and occurred in 42% of patients overall, but in 70% of rFVIIa-treated patients. Transient cessation or reduction of bleeding was noted in 60% of patients following rFVIIa infusion. However, 24-h and 7-day mortality rates were 40% and 70%, respectively, in this group. Conclusions Last-ditch rFVIIa therapy in patients resistant to conventional treatment did not rescue these patients or significantly alter outcomes.
引用
收藏
页码:120 / 124
页数:5
相关论文
共 14 条
[1]   CLOTTING FACTOR LEVELS AND THE RISK OF DIFFUSE MICROVASCULAR BLEEDING IN THE MASSIVELY TRANSFUSED PATIENT [J].
CIAVARELLA, D ;
REED, RL ;
COUNTS, RB ;
BARON, L ;
PAVLIN, E ;
HEIMBACH, DM ;
CARRICO, CJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1987, 67 (03) :365-368
[2]   Final statement [J].
Contreras, M .
BLOOD REVIEWS, 1998, 12 (04) :239-240
[3]   Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy:: a double-blind placebo-controlled andomised trial [J].
Friederich, PW ;
Herny, CP ;
Messelink, EJ ;
Geerdink, MG ;
Keller, T ;
Kurth, KH ;
Büller, HR ;
Levi, M .
LANCET, 2003, 361 (9353) :201-205
[4]   MASSIVE BLOOD-TRANSFUSION IN A TERTIARY REFERRAL HOSPITAL - CLINICAL OUTCOMES AND HEMOSTATIC COMPLICATIONS [J].
HARVEY, MP ;
GREENFIELD, TP ;
SUGRUE, ME ;
ROSENFELD, D .
MEDICAL JOURNAL OF AUSTRALIA, 1995, 163 (07) :356-359
[5]   HEMOSTATIC FACTORS AND REPLACEMENT OF MAJOR BLOOD-LOSS WITH PLASMA-POOR RED-CELL CONCENTRATES [J].
HIIPPALA, ST ;
MYLLYLA, GJ ;
VAHTERA, EM .
ANESTHESIA AND ANALGESIA, 1995, 81 (02) :360-365
[6]   A new approach to treatment of bleeding episodes in young hemophilia patients:: a single bolus megadose of recombinant activated factor VII (NovoSeven®) [J].
Kenet, G ;
Lubetsky, A ;
Luboshitz, J ;
Martinowitz, U .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) :450-455
[7]   Treatment of traumatic bleeding with recombinant factor VIIa [J].
Kenet, G ;
Walden, R ;
Eldad, A ;
Martinowitz, U .
LANCET, 1999, 354 (9193) :1879-1879
[8]   Pharmacological approaches to reducing allogeneic blood exposure [J].
Kovesi, T ;
Royston, D .
VOX SANGUINIS, 2003, 84 (01) :2-10
[9]   Analysis and results of the recombinant factor VIIa extended-use registry [J].
Laffan, M ;
O'Connell, NM ;
Perry, DJ ;
Hodgson, AJ ;
O'Shaughnessy, D ;
Smith, OP .
BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 :S35-S38
[10]   Recombinant activated factor VII for adjunctive hemorrhage control in trauma [J].
Martinowitz, U ;
Kenet, G ;
Segal, E ;
Luboshitz, J ;
Lubetsky, A ;
Ingerslev, J ;
Lynn, M .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2001, 51 (03) :431-438